Phase 4 N=4 BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients
Epilepsy
Primary: AUC — 79640; 81653 ng*hr/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=706 A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Melanoma
Primary: Progression-free Survival — 4.7; 4.9 months — p=0.51711
Phase 1 N=44 Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects
Safety · Healthy Subjects
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 4; 2; 5 Participants
Phase 3 N=511 Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Multidrug-resistant Tuberculosis
Primary: Time To Sputum Culture Conversion (SCC) During 6-Month Intensive Period Using The Mycobacteria Growth Indicator Tube (MGIT) System — 51; 57 Days — p=0.0562
N/A N=40 Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants
HIV Infections
Primary: PK Parameter: Neonatal RAL Elimination Half-life (T1/2) — 26.6; 24.4 Hours
N/A N=199 Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail
Alcohol Drinking · Marijuana Smoking
Primary: Alcohol Use, Average # of Drinks Per Week — 11.16; 10.62; 5.16; 3.86 average # of drinks per week
Phase 2 N=133 A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
Epilepsy
Primary: Change From Baseline to Week 19 in Cognition Drug Research (CDR) System Global Cognition Score (Core Study) — -1.0; 1.1 Scores on a scale
N/A N=177 Predictive Value of the FORE-SIGHT™ Monitor for Hemodynamic Deterioration
Pediatric Congenital Heart Surgery
Primary: The Accuracy to Predict Acute Kidney Injury (AKI) Per Patient, 6 Hours Before This Clinical Event (AKI) Occurs — 55 Participants
Phase 2 N=63 Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Pulmonary Hypertension
Primary: Number of Participants Experiencing Significant Fluid Retention or Worsening in NYHA Functional Class (FC) up to End-of-treatment — 7; 4; 7; 3 Participants — p=0.3372
Phase 2 N=17 Dichotic Listening as a Predictor of Medication Response in Depression
Major Depression · Dysthymia · Depressive Disorder Not Otherwise Specified
Primary: Hamilton Depression Scale (HAM-D) — 10; 9 score on a scale
N/A N=41 Zip Arthroplasty Patient Satisfaction Evaluation
Knee Arthroplasty
Primary: Patient and Observer Scar Assessment Scale (POSAS) — 2.25; 3.40; 1.10; 2.29 score on a scale
Phase 2 N=39 Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Schizophrenia · Cognition · Psychosis
Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 36.6; 32.9; 36.3; 33.8 Score on a Scale
N/A N=40 Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy
Biliary Colic · Cholecystitis
Primary: Operative Time — 86.5; 31.5 minutes
Phase 2 N=17 CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months
N/A N=26 Pregabalin in CIPN
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient